Teva launches generic migraine treatment

Teva

Teva is the first applicant to receive approval and will have market exclusivity for generic Axert until November.

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) has launched generic Axert (almotriptan malate) tablets in 6.25 mg and 12.5 mg dosages, in the US. The treatment is for migraine. Teva is the first applicant to receive approval and will have a period of market exclusivity until the pediatric exclusivity associated with the only patent for Axert expires on November 7, 2015.

Teva continues to deliver on its generics business strategy and remains focused on increasing its first to file regulatory submissions in the US. With over 375 generic medicines available, Teva has the largest portfolio of safe, effective, US Food and Drug Administration (FDA) -approved generic products on the market.

Axert (almotriptan malate) tablets, marketed by Janssen Pharmaceuticals, had annual sales of approximately $31 million in the US, according to IMS data as of March 2015.

Published by Globes [online], Israel business news - www.globes-online.com - on July 9, 2015

© Copyright of Globes Publisher Itonut (1983) Ltd. 2015

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018